Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres
- PMID: 18978442
- DOI: 10.1088/0031-9155/53/22/019
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres
Erratum in
- Phys Med Biol. 2014 May 21;59(10):2549-51. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text
Abstract
Selective internal radiotherapy (SIRT) using Yttrium-90 labeled resin microspheres is increasingly used for the radioembolization of unresectable liver metastases of colorectal cancer (CRC). The treatment can be simulated by scintigraphy with Tc(99m)-labeled macroaggregates of albumin (MAA). The aim of the study was to develop a predictive dosimetric model for SIRT and to validate it by correlating results with the metabolic treatment response. The simulation of the dosimetry was performed by mathematically converting all liver voxel MAA-SPECT uptake values to the absolute Y(90) activity. The voxel values were then converted to a simulated absorbed dose (Gy) using simple MIRD formalism. The metabolic response was defined as the change in total lesion glycolysis (TLG) on FDG-PET. A total of 39 metastatic liver lesions were studied in eight evaluable patients. The mean administered Y(90) activity was 1.69 GBq (range: 1.33-2.04 GBq). The median (95% CI) simulated absorbed dose (Gy) was 29 Gy (1–98 Gy) and 66 Gy(32–159 Gy) in the poor (<50% TLG change) and the good responders (TLG change > 50%),respectively [DOSAGE ERROR CORRECTED].Using a simple cut-off value of 1 for the MAA-tumor-to-normal uptake ratio, a significant metabolic response was predicted with a sensitivity of 89% (17/19), a specificity of 65% (13/20), a positive predictive value of 71% (17/24) and a negative predictive value of 87% (13/15). Integrated multimodality imaging allows prediction of metabolic response post radioembolization using Y(90)-resin microspheres, and should be used for patient selection.
Similar articles
-
Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.J Nucl Med. 2016 Jul;57(7):1014-9. doi: 10.2967/jnumed.115.166942. Epub 2016 Feb 23. J Nucl Med. 2016. PMID: 26912436 Clinical Trial.
-
Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.J Vasc Interv Radiol. 2014 Feb;25(2):288-95. doi: 10.1016/j.jvir.2013.08.021. Epub 2013 Oct 23. J Vasc Interv Radiol. 2014. PMID: 24269792
-
Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.J Nucl Med. 2013 Apr;54(4):516-22. doi: 10.2967/jnumed.112.112508. Epub 2013 Feb 27. J Nucl Med. 2013. PMID: 23447653
-
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.Q J Nucl Med Mol Imaging. 2011 Apr;55(2):168-97. Q J Nucl Med Mol Imaging. 2011. PMID: 21386789 Review.
-
State of the art: radiolabeled microspheres treatment for liver malignancies.Expert Opin Pharmacother. 2010 Mar;11(4):579-86. doi: 10.1517/14656560903520916. Expert Opin Pharmacother. 2010. PMID: 20163269 Review.
Cited by
-
Fabrication of quantum dot-immobilized Y2O3 microspheres with effective photoluminescence for cancer radioembolization therapy.Sci Technol Adv Mater. 2024 Apr 2;25(1):2331412. doi: 10.1080/14686996.2024.2331412. eCollection 2024. Sci Technol Adv Mater. 2024. PMID: 38572410 Free PMC article.
-
Prospective comparison of positron emission tomography (PET)/magnetic resonance and PET/computed tomography dosimetry in hepatic malignant neoplastic disease after 90Y radioembolization treatment.J Gastrointest Oncol. 2024 Feb 29;15(1):356-367. doi: 10.21037/jgo-23-890. Epub 2024 Feb 26. J Gastrointest Oncol. 2024. PMID: 38482235 Free PMC article.
-
Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):947-950. doi: 10.1007/s00259-023-06568-8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38110711 Free PMC article. No abstract available.
-
Trans-arterial Radioembolization Dosimetry in 2022.Cardiovasc Intervent Radiol. 2022 Nov;45(11):1608-1621. doi: 10.1007/s00270-022-03215-x. Epub 2022 Aug 18. Cardiovasc Intervent Radiol. 2022. PMID: 35982334 Review.
-
TCP post-radioembolization and TCP post-EBRT in HCC are similar and can be predicted using the in vitro radiosensitivity.EJNMMI Res. 2022 Jul 8;12(1):40. doi: 10.1186/s13550-022-00911-0. EJNMMI Res. 2022. PMID: 35802307 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical